NovaBay Pharmaceuticals, Inc. (NBY)

The past six months have seen significant volatility. The stock experienced substantial swings, including a surge of over 100% in a single day in January 2026, but also saw sharp declines. NovaBay Pharmaceuticals shares plunged as investors reacted to news that the company's longtime auditor declined to stand for re-appointment for fiscal year 2025. In August 2025, NovaBay announced a one-time special cash dividend of $0.80 per share. In January 2026, NovaBay plunged on news of a sales agreement for a $100 million stock offering. In October 2025, NovaBay Pharmaceuticals regained compliance with the NYSE American's continued listing standards. Recent insider filings showing former 10% owner David Lazar's stake reshuffling may have further pressured sentiment. The last stock split for NBY was a 1:35 reverse split on May 31, 2024.

Information specifically detailing the demand seasonality for NovaBay Pharmaceuticals, Inc.'s products and services is not readily available.

NovaBay Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and selling scientifically-created and clinically-proven eyecare and skincare products. The company aims to deliver accessible, non-antibiotic solutions for infection control and inflammation management, particularly in eyecare and wound care. Its major products include Avenova Antimicrobial Lid and Lash Solution, NeutroPhase, i-Lid Cleanser, Nexagon, and DERMAdoctor. As of late 2025, NovaBay Pharmaceuticals was transitioning to focus on manufacturing proprietary wound care products for export and exploring new strategic directions in emerging financial infrastructure and blockchain-based markets.

NovaBay Pharmaceuticals sells its wound care products to distribution partners in China. Its FDA clearances and CE marks support distribution across the United States, Canada, Europe, and select international markets through strategic partnerships. The company is headquartered in Emeryville, California, United States.

NovaBay Pharmaceuticals' brand reputation has been influenced by its market performance and strategic shifts. The company is in a critical transition phase, pivoting from a niche eye and skin care company to one focused on wound care and exploring new financial and blockchain markets. The decision by its longtime auditor to not stand for re-appointment for fiscal year 2025 likely raised concerns. Shareholders have been substantially diluted in the past year.

Individual Insiders hold the largest portion, approximately 49.2% of shares outstanding. VC/PE Firms own about 44.2% of the company. The General Public holds approximately 4.28% of shares outstanding. Institutional Owners comprise 2.37% of the shares outstanding. Major institutional shareholders include Vanguard Group Inc, Geode Capital Management, LLC, and UBS Group AG.